Contents:

1 Executive Summary 2 Methodologies 3 Table of Contents 3.1 List of Figures 3.2 List of Tables 3.3 List of Boxes 4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting? 5 Antibody Drug Targets by Molecular Function 5.1 Carboxypeptidase Activity Targets 5.2 Catalytic Activity Targets 5.3 Cell Adhesion Molecule Activity Targets 5.4 Chaperone Activity Targets 5.5 Chemokine Activity Targets 5.6 Cofactor Binding Targets 5.7 Complement Activity Targets 5.8 Cytokine Activity Targets 5.9 DNA Topoisomerase Activity Targets 5.10 Extracellular Matrix Structural Constituent Targets 5.11 G-protein Coupled Receptor Activity Targets 5.12 Growth Factor Activity Targets 5.13 Hormone Activity Targets 5.14 Hydrolase Activity Targets 5.15 Intracellular Ligand-gated Ion Channel Activity Targets 5.16 Metallopeptidase Activity Targets 5.17 MHC Class I Receptor Activity Targets 5.18 Molecular Function Unknown Targets 5.19 Oxidoreductase Activity Targets 5.20 Peptide Hormone Targets 5.21 Protease Inhibitor Activity Targets 5.22 Protein Binding Targets 5.23 Receptor Activity Targets 5.24 Receptor Binding Targets 5.25 Receptor Signaling Complex Scaffold Activity Targets 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 5.27 RNA-directed DNA polymerase Activity Targets 5.28 Serine-type Peptidase Activity Targets 5.29 T Cell Receptor Activity Targets 5.30 Translation Regulator Activity Targets 5.31 Transmembrane Receptor Activity Targets 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 5.33 Transporter Activity Targets 5.34 Unclassified Targets 6 Antibody Drugs Targeting Signaling Pathways 6.1 Alpha6 Beta4 Integrin Signaling Pathway 6.1.1 Description of Pathway 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.2 Androgen Receptor Signaling Pathway 6.2.1 Description of Pathway 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.3 B Cell Receptor Signaling Pathway 6.3.1 Description of Pathway 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.4 EGFR1 Signaling Pathway 6.4.1 Description of Pathway 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.5 IL-2 Signaling Pathway 6.5.1 Description of Pathway 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.6 IL-4 Signaling Pathway 6.6.1 Description of Pathway 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type 6.7 IL-6 Signaling Pathway 6.7.1 Description of Pathway 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.8 Kit Receptor Signaling Pathway 6.8.1 Description of Pathway 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.9 Notch Signaling Pathway 6.9.1 Description of Pathway 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.10 T Cell Receptor Signaling Pathway 6.10.1 Description of Pathway 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.11 TGF-beta Receptor Signaling Pathway 6.11.1 Description of Pathway 123 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type 6.12 TNF-alpha Signaling Pathway 6.12.1 Description of Pathway 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 6.13 Wnt Signaling Pathway 6.13.1 Description of Pathway 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type 7 Antibodies Targeting Cancer Stem Cells 8 Targets of Antibody Conjugates 9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects 9.1 Anti-Angiogenesis 9.2 Apoptosis 9.3 Protein Kinase Inhibitors 10 Antibody Targets and Drugs by Cancer Indications 10.1 Basal Cell Cancer 10.2 Biliary Cancer 10.3 Bladder Cancer 10.4 Bone Cancer 10.5 Brain Cancer 10.6 Breast Cancer 10.7 Cervical Cancer 10.8 Cervical Dysplasia 10.9 Colorectal Cancer 10.10 Endometrial Cancer 10.11 Esophageal Cancer 10.12 Fallopian Tube Cancer 10.13 Gastrointestinal Cancers 10.14 Head and Neck Cancer 10.15 Leukemias 10.16 Liver Cancer 10.17 Lung Cancers 10.18 Lymphomas 10.19 Melanoma 10.20 Mesothelioma 10.21 Myelodysplastic syndrome 10.22 Myelomas 10.23 Nasopharyngeal Cancer 10.24 Oesophageal Cancer 10.25 Ovarian Cancer 10.26 Pancreatic Cancer 10.27 Peritoneal Cancer 10.28 Prostate Cancer 10.29 Renal Cancers 10.30 Sarcomas 10.31 Thyroid Cancer 11 Expression Profiles of Antibody Drug Targets 11.1 Human Tissues and Cancer Tissues 11.2 Cancer Lines and Cells 12 Breast Cancer: An Introduction 12.1 Disease Definitions 12.2 Etiology 12.3 Epidemiology 12.4 Prognosis 13 Current Treatment Strategies of Breast cancer 13.1 Localized Disease 13.2 Advanced Disease 14 Progress in Current Breast Cancer Treatment Strategies 14.1 Hormone Based Therapies 14.2 Antibodies 14.3 Chemotherapy 14.4 Chemotherapy 15 Key Therapeutic Strategies for Future Breast Cancer Therapies 15.1 Therapeutic Type, Targets & Mechanisms 16 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline 16.1 The Epothilones 16.2 Cell Cycle & Apoptosis 16.3 Protein Kinase Inhibitors 16.4 Immunotherapy 17 Current Drug Development for Breast Cancer: The Early Stage Pipeline 17.1 DNA Targeting 17.2 FTIs 17.3 Antisense 17.4 New Hormone Modulators 17.5 Other 18 Prostate Cancer: An Introduction 18.1 Disease Definitions 18.2 Etiology & Pathophysiology 18.3 Epidemiology 18.4 Prognosis 19 Current Prostate Cancer Treatment Strategies 19.1 Localized Disease 19.1.1 Locally Advanced Prostate Cancer 19.2 Metastatic Prostate Cancer 19.2.1 Hormone-Sensitive Metastatic Prostate Cancer 19.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer 20 Progress in Current Prostate CancerTreatment Strategies 20.1 Long-Term Follow-up Data not yet Been Published 20.2 Significant Reduced Risk of Distant Metastases 20.3 Adverse Events 20.4 No Difference in Overall Survival 20.5 Cross-over Design an Optimal Option? 20.6 Death due to Liver Failure 20.7 Survival Benefit 20.8 Subdermal Implant 20.9 No FDA Approval 20.10 No Improvement in 5-year Disease-Free Survival 20.11 Effective Secondary Hormonal Therapy? 20.12 Synery in Combination 21 Key Therapeutic Strategies for Future Prostate Cancer Therapies 21.1 Therapeutic Type, Targets & Mechanisms 22 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline 22.1 Reduced Prostate Cancer Risk 22.2 High Activity in Metastatic AIPC Patients 22.3 Absence of Severe Toxicities 22.4 Waiting for Data 22.5 Probability of Regulatory Approval? 22.6 Co-development and License Agreement 22.7 Improves Predicted Survival? 22.8 Slow Progress & Development Partners 22.9 Exclusive License Agreement 23 Current Prostate Cancer Drug Development: The Early Stage Pipeline 23.1 New Data? 23.2 Terminated Study 23.3 More Than 50% PSA decline 23.4 Safety and Tolerability 23.5 Terminated? 23.6 Marker of Drug Effect 23.7 Preliminary Results for a Tyrosine Kinase Inhibitor 23.8 No Activity in Monotherapy 23.9 Dramatic Disappearance of Bone Metastatic Lesions 23.10 PSA Response - Anthracycline 24 Disclaimer 25 Drug Index 26 Company Index 27 Appendix I: Antibody Targets by Companies 3.1 List of Figures Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3) Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3) Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3) Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target Figure 6: Pipeline Maturation of Catalytic Activity Targets Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target Figure 10: Pipeline Maturation of Chaperone Activity Targets Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target Figure 12: Pipeline Maturation of Chemokine Activity Targets Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target Figure 14: Pipeline Maturation of Cofactor Binding Targets Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target Figure 16: Pipeline Maturation of Complement Activity Targets Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target Figure 18: Pipeline Maturation of Cytokine Activity Targets Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target Figure 26: Pipeline Maturation of Growth Factor Activity Targets Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target Figure 28: Pipeline Maturation of Hormone Activity Targets Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target Figure 30: Pipeline Maturation of Hydrolase Activity Targets Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target Figure 38: Pipeline Maturation of Molecular Function Unknown Targets Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target Figure 42: Pipeline Maturation of Peptide Hormone Targets Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target Figure 46: Pipeline Maturationof Protein Binding Targets Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2) Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2) Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2) Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2) Figure 52: Pipeline Maturationof Receptor Binding Targets Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target Figure 62: Pipeline Maturation of T cell Receptor Activity Targets Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target Figure 64: Pipeline Maturation of Translation Regulator Activity Targets Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target Figure 70: Pipeline Maturation of Transporter Activity Targets Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target Figure 72: Pipeline Maturation of Unclassified Targets Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target 3.2 List of Tables Table 1: Molecular Functions versus Oncology Antibody Drug Targets Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets. Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets Table 36: Antibody Drugs Targeting Signaling Pathways Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target Table 67: Immunoconjugated Antibody Pipeline According to Target Table 68: Antibodies in Oncology Reported to Affect Angiogenesis Table 69 Antibodies in Oncology Reported to Affect Apoptosis Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage Table 73: Antibody Pipeline by Targets in Basal Cell Cancer Table 74: Antibody Pipeline by Targets in Biliary Cancer Table 75: Antibody Pipeline by Targets in Bladder Cancer Table 76: Antibody Pipeline by Targets in Bone Cancer Table 77: Antibody Pipeline by Targets in Brain Cancer Table 78: Antibody Pipeline by Targets in Breast Cancer Table 79: Antibody Pipeline by Targets in Cervical Cancer Table 80: Antibody Pipeline by Targets in Cervical Dysplasia Table 81: Antibody Pipeline by Targets in Colorectal Cancer Table 82: Antibody Pipeline by Targets in Endometrial Cancer Table 83: Antibody Pipeline by Targets in Esophageal Cancer Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers Table 86: Antibody Pipeline by Targets in Head and Neck Cancer Table 87: Antibody Pipeline by Targets in Leukemias Table 88: Antibody Pipeline by Targets in Liver Cancer Table 89: Antibody Pipeline by Targets in Lung Cancers Table 90: Antibody Pipeline by Targets in Lymphomas Table 91: Antibody Pipeline by Targets in Melanoma Table 92: Antibody Pipeline by Targets in Mesothelioma Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome Table 94: Antibody Pipeline by Targets in Myelomas Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer Table 96: Antibody Pipeline by Targets in Oesophageal Cancer Table 97: Antibody Pipeline by Targets in Ovarian Cancer Table 98: Antibody Pipeline by Targets in Pancreatic Cancer Table 99: Antibody Pipeline by Targets in Peritoneal Cancer Table 100: Antibody Pipeline by Targets in Prostate Cancer Table 101: Antibody Pipeline by Targets in Renal Cancers Table 102: Antibody Pipeline by Targets in Sarcomas Table 103: Antibody Pipeline by Targets in Thyroid Cancer Table 104: Expression Profiles of Antibody Drug Targets in Oncology Table 105: The Stage System Table 106: Risk Factors Table 107: List of Approved Drugs and Their Mechanisms of Action. Table 108: Hormonal Treatment Strategies Table 109: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer Table 110: Treatment Options for Women With Axillary Node-Positive Breast Cancer. Table 111: Chemotherapy Drugs and Regimen Table 112: Summay of Drugs Involved in Breast Cancer Therapy Table 113: Short Facts Tamoxifen Table 114: Short Facts Anastrozole Table 115: Short Facts Letrozole Table 116: Short Facts Exemestane Table 117: Short Facts Goserelin Table 118: Short Facts Fulvestrant Table 119: Short Facts Trastuzumab Table 120 Cancer Immunotherapy Strategies Table 121: Progress on Ixabepilone Table 122: Progress on CCI-779 Table 123: Progress on Fenretinide Table 124: Progress on Lapatinib Table 125: Progress on Bevacizumab Table 126: Progress on Theratope Table 127: Summary of Mid-Stage to Late stage Investigational Agents Under Development Table 128: Summary of Breast Cancer Early Stage Pipeline Table 129: The TNM System Table 130: Lifestyle factors Table 131: Historical Summary of Clinical Studies on Patients with Late Stage Disease Table 132: Short Facts Abarelix Table 133: Short Facts Bicalutamide Table 134: Short Facts Carboplatin Table 135: Short Facts Docetaxel Table 136: Short Facts Mitoxantrone Table 137: Short Facts Flutamide Table 138: Short Facts Goserelin Table 139: Short Facts Histrelin Table 140: Short Facts Lanreotide Table 141: Short Facts Leuprolide Table 142: Short Facts Nilutamide Table 143: Short Facts Estramustine Table 144: Summary of Recent Clinical Studies on Patients with Late Stage Disease Table 145: Ongoing Late Stage Clinical Studies Table 146: Cancer Immunotherapy Strategies Table 147: Near Term Progress Toremifene Table 148: Near Term Progress Bevacizumab Table 149: Near Term Progress Oblimersen Table 150: Near Term Progress R-flurbiprofen Table 151: Near Term Progress APC8015 Table 152: Near Term Progress Satraplatin Table 153: Near Term Progress GVAX Table 154: Near Term Progress Exisulind Table 155: Summary of Prostate Cancer Late Stage Pipeline Table 156: Paclitaxel Table 157: Epothilone Table 158: Ixabepilone Table 159: PTK/ZK Table 160: Arsenic trioxide Table 161: Retinoic Acid Table 162: Imatinib Table 163: Bortezomib Table 164: Sorafenib Table 165: Doxorubicin Table 166: Summary of Prostate Cancer Early Stage Pipeline

Companies Mentioned

- Abgenix - AbGenomics - Abiogen - Actinium Pharmaceuticals - Adherex - Affibody - Affimed Therapeutics - Agensys - AGY Therapeutics - Aida Pharmaceuticals - Alexion - Alfacell - Amgen - Antisoma - Aphton - ARIUS Research - AstraZeneca - Attenuon - AVEO - Avidex - Bayer - Bayer Schering - Berkeley Lab - Biogen Idec - BioInvent - Biotecnol - Bristol-Myers Squibb - BTG - Cancer Research Technology - Celldex - Cellerant Therapeutics - Celtic Pharma - Center of Molecular Immunology - CuraGen - Cytogen - Daiichi Sankyo - Debiopharm - Dendreon - Diversa - Domantis - Dyax - Eli Lilly - EvoGenix - Exelixis - FibroGen - Galaxy Biotech - Genencor - Genentech - Genzyme - GlaxoSmithKline - GTC Biotherapeutics - Hoffmann-La Roche - Human Genome Sciences - ImClone Systems - ImmunoGen - Immunomedics - InSight - Intracel - Johnson & Johnson - Kirin Brewery - Kissei - Kyowa Hakko - Kyto Biopharma - Ligand - MacroGenics - Medarex - MediGene - MedImmune - Menarini - Merck & Co - Merck KGaA - Micromet - Millennium - MorphoSys - Morphotek - NIH - Non-industrial source - Novartis - OncoMab - OncoMed - Ono - Onyvax - OPi - Oxford BioMedica - Panacea - PanGenetics - PDL BioPharma - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre - Prima Biomed - Prochon Biotech - Receptor BioLogix - Regeneron - Scancell - Seattle Genetics - Sigma-Tau - Sirtex Medical - Somanta - Sunol Molecular - Switch Pharma - Tanox - TolerRx - Tracon Pharmaceuticals - Trillium Therapeutics - Trion Pharma - UCB - Vaccinex - Valentis - VasGene Therapeutics - Viragen - ViRexx - Viventia Biotech - Wilex - Xencor - Xerion - Xoma